Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Pakeeza Sayyed"'
Autor:
Simon Allen, Y-K. Kang, J. Decalf, S. Iqbal, Pakeeza Sayyed, J.W. Lee, Shengfu Li, Y-J. Bang, H.C. Chung, N. Al-Sakaff, J. Pintoffl, Jaffer A. Ajani
Publikováno v:
Annals of Oncology. 32:S1047
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee073f76a71447c12978bba5d553a493
https://doi.org/10.1016/j.annonc.2021.08.1491
https://doi.org/10.1016/j.annonc.2021.08.1491
Autor:
Marwan Fakih, Jochen Schulze, Pakeeza Sayyed, Lorna Bailey, Yong Sang Hong, Simon Allen, Michael Cecchini, Christelle Lenain, Danny Lu, Katrina S. Pedersen, Neil H. Segal, Jayesh Desai
Publikováno v:
Journal of Clinical Oncology. 39:82-82
82 Background: The MORPHEUS platform consists of multiple, global, open-label, randomized Phase Ib/II trials designed to identify early efficacy signals and safety of treatment (tx) combinations across tumor types. Isatuximab (isa; anti-CD38) targets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2ac4d5bd4635e0386195ee9c2434bdd
https://doi.org/10.1200/jco.2021.39.3_suppl.82
https://doi.org/10.1200/jco.2021.39.3_suppl.82
Autor:
Sai Li, Sarit Assouline, Gianluca Gaidano, Valeria Buccheri, Alain Delmer, Pakeeza Sayyed, Natalia Berthillon, Olivier Catalani, Xavier Badoux, Michael Brewster, Marek Trneny, Christine McIntyre
Publikováno v:
The Lancet Haematology. 3:e128-e138
Summary Background Part one of the two-part SAWYER study predicted that subcutaneous rituximab 1600 mg would achieve trough serum concentrations that were non-inferior to those achieved with intravenous rituximab 500 mg/m 2 in patients with chronic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d31ee5568f0280de03cd792f8a53b9
https://doi.org/10.1016/s2352-3026(16)00004-1
https://doi.org/10.1016/s2352-3026(16)00004-1
Autor:
Ben Solomon, Melissa Lynne Johnson, Simon Allen, Pakeeza Sayyed, Lorna Bailey, Mary O'Brien, J. Pintoffl, Bhumsuk Keam, A. Swalduz, Victor Moreno, J. Mazieres, Farah Louise Lim, E. Felip, H-J. Helms, N. Al-Sakaff, Sarah B. Goldberg, Colby S. Shemesh, Fabrice Barlesi, Byoung Chul Cho, Valentina Boni
Publikováno v:
Annals of Oncology. 31:S850
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c8e5e59dbcb9241464d5cf84070c15a
https://doi.org/10.1016/j.annonc.2020.08.1629
https://doi.org/10.1016/j.annonc.2020.08.1629
Autor:
Edward Cha, Melissa Lynne Johnson, Pakeeza Sayyed, Farah Louise Lim, Enriqueta Felip, Johanna C. Bendell, Kyu-Pyo Kim, Xiaosong Zhang, Yoon-Koo Kang, Do-Youn Oh, Hans-Joachim Helms, Simon Allen, Osama E. Rahma, Teresa Macarulla, J. Pintoffl, Gulam Abbas Manji, Byoung Chul Cho, Denise Cotting, Nathan Bahary
Publikováno v:
Cancer Research. 80:CT201-CT201
Background: The MORPHEUS platform comprises multiple Phase Ib/II trials to identify early efficacy signals and safety of treatment combinations across cancers. Within MORPHEUS, atezolizumab (atezo), a PD-L1 inhibitor, was tested in combination with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cf9e683dc7e979f210e205e3a4da766
https://doi.org/10.1158/1538-7445.am2020-ct201
https://doi.org/10.1158/1538-7445.am2020-ct201
Autor:
Sarah Liptrott, Nicola Crosbie, Maris Stella Sugino, Renate Bratke, Maria Mendoza, Pakeeza Sayyed
Publikováno v:
Cancer Nursing Practice. 14:29-37
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::733422dec0ce72a759c7e1fda854ecb5
https://doi.org/10.7748/cnp.14.8.29.s22
https://doi.org/10.7748/cnp.14.8.29.s22
Autor:
Florence Hourcade-Potelleret, Sarit Assouline, Olivier Catalani, Xavier Badoux, Michael Brewster, Alain Delmer, Pakeeza Sayyed, Gianluca Gaidano, Valeria Buccheri, Christine McIntyre
Publikováno v:
British Journal of Clinical Pharmacology. 80:1001-1009
Aims The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7148ec79bb17cb32ad4bc84dded2976
https://doi.org/10.1111/bcp.12662
https://doi.org/10.1111/bcp.12662
Autor:
Irit Avivi, Pakeeza Sayyed, Andrea Janíková, Christine McIntyre, Reda Bouabdallah, Olivier Catalani, Mike Brewster, Juliana Pereira, Antonio Salar, Ofer Shpilberg, Jean-François Larouche, George A. Follows, Gayane Tumyan, Florence Hourcade-Potelleret, Beate Bittner, Andrew P. Haynes, Michael Pedersen
Publikováno v:
Journal of Clinical Oncology. 32:1782-1791
Purpose This two-stage phase IB study investigated the pharmacokinetics and safety of subcutaneous (SC) versus intravenous (IV) administration of rituximab as maintenance therapy in follicular lymphoma. Patients and Methods In stage 1 (dose finding),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a76f6377fa2a06b316b3bade7af745eb
https://doi.org/10.1200/jco.2013.52.2631
https://doi.org/10.1200/jco.2013.52.2631
Autor:
S.L. McCune, I. Chau, Teresa Macarulla, Ben Solomon, Melissa Lynne Johnson, Sami Mahrus, Peter Schmid, Guillem Argiles, Georg Martin Haag, K. Dimick, Xian He, Osama E. Rahma, Conrad Bleul, G.A. Vidal, Edward Cha, A. Drakaki, Hussein A. Abdullah, Denise A. Yardley, Pakeeza Sayyed, Hila Barak
Publikováno v:
Annals of Oncology. 29:viii439-viii440
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8781a0579ec35371993df34f4e5748e9
https://doi.org/10.1093/annonc/mdy288.110
https://doi.org/10.1093/annonc/mdy288.110
Autor:
Salah-Eddin Al-Batran, Eileen M. O'Reilly, Do-Youn Oh, Edward Cha, Xiaosong Zhang, Hila Barak, Kyu-Pyo Kim, Antoine Hollebecque, Osama E. Rahma, Gulam Abbas Manji, Syma Iqbal, Pakeeza Sayyed, Jill Lacy, Jun Wang, Tanios Bekaii-Saab, Antonia Kwan, Xian He, Hyun Cheol Chung, Harry H. Yoon
Publikováno v:
Journal of Clinical Oncology. 36:TPS4134-TPS4134
TPS4134Background: Multiple cancers have been treated successfully with CIT; nonetheless, only subsets of pts experience durable response with CIT monotherapy. CIT combinations may therefore be nee...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c6562b3381351620cbfec6d4f6938ce
https://doi.org/10.1200/jco.2018.36.15_suppl.tps4134
https://doi.org/10.1200/jco.2018.36.15_suppl.tps4134